MT awarded NCI SBIR Phase II grant

11/01/2022

Molecular Theranostics has been awarded a two-year, $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Award to study the magnetic imaging efficacy of MT218 in prostate cancer patients and safety, after successfully completing a clinical trial in 30 healthy volunteers.

​

Funded by the NIH, the award supports a diverse portfolio of startups and small businesses across technology areas and markets to stimulate technological innovation, meet Federal research and development (R&D) needs, and increase commercialization to transition R&D into impact.